Key result
Isorhamnetin prevents doxorubicin-induced testicular toxicity and spermatogenic damage in preclinical models.
Why the study?
Male reproductive damage is one of the most adverse side effects of doxorubicin, and the protective effects of isorhamnetin against such damage were assessed.
Does isorhamnetin prevent doxorubicin-induced testicular damage in adult male Wistar rats?
Does isorhamnetin prevent doxorubicin-induced testicular damage in adult male Wistar rats?
Isorhamnetin mitigates doxorubicin-induced testicular damage in a rat model by regulating steroidogenic enzymes and apoptotic signaling.
Hypothesis-generating for isorhamnetin in doxorubicin gonadal protection; leaves open clinical translation and should not change practice.
Background: Male reproductive damage is one of the most adverse side effects of doxorubicin (DOX). Isorhamnetin is a natural flavonoid, which displays remarkable antioxidant potential. Objective: The current research was designed to assess the protective effects of Isorhamnetin against DOX-instigated testicular damages. Methods: Adult male Wistar rats (n=32) were divided into 4 groups: control, DOX (3 mg/kg i.p. 3 doses each after 1 week), DOX + Isorhamnetin (3 mg/kg 3 doses each after 1 week +10 mg/kg i.p. daily for 28 days, respectively), and Isorhamnetin (10 mg/kg i.p. per day). After 28 days of treatment, biochemical, spermatogenic, steroidogenic, hormonal, proapoptotic, antiapoptotic, and histopathological parameters were estimated. Results: DOX exposure significantly decreased the activity of acid phosphatase, lactate dehydrogenase, and gamma-glutamyl transferase. Furthermore, DOX substantially decreased the activities of antioxidant enzymes, i.e. catalase, superoxide dismutase, glutathione reductase, and glutathione peroxidase along with protein content, whereas it increased the malondialdehyde level. It also reduced sperm progressive motility, viability, the number of hypoosmotic tail swelled spermatozoa, and epididymis sperm count and increased the sperm morphological anomalies (head, midpiece, and tail). Besides, it decreased the levels of follicle-stimulating hormone, luteinizing hormone, and plasma testosterone and lowered the expression of steroidogenic enzymes (3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase, and steroidogenic acute regulatory protein) and testicular antiapoptotic marker (B-cell lymphoma 2) but increased the expression of proapoptotic markers (BCL2-associated X protein and caspase-3) along with histopathological impairments. However, isorhamnetin prevented all the damages caused by DOX. Conclusion: Conclusively, Isorhamnetin can be used as a powerful mitigating agent to avert DOX-induced testicular damages.
No takes yet. Share an insight, caveat, or question.
Mustafa et al. (2022) studied Doxorubicin-induced testicular injury (n=32). Isorhamnetin vs. Doxorubicin alone was evaluated on Biochemical, spermatogenic, steroidogenic, hormonal, proapoptotic, antiapoptotic, and histopathological parameters. Isorhamnetin prevented doxorubicin-induced testicular damage, including biochemical, spermatogenic, hormonal, and histopathological impairments in male rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: